Physician profile
Mark P Tanenbaum
NPI 1114929247
$1,979.31
in general payments reported to CMS, 2019-2025
22 companies · $18.77 in 2025
The $18.77 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,046 · 2020: $75.83 · 2021: $160 · 2022: $336 · 2023: $133 · 2024: $210 · 2025: $18.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $361.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $409.74 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $214.57 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $167.92 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $163.78 | 2019-2024 | |
| Pfizer INC. | $145.92 | 2019-2024 | |
| Medtronic Vascular, INC. | $125.00 | 2019 | |
| Amarin Pharma, INC. | $124.15 | 2019-2021 | |
| Medtronic, INC. | $111.15 | 2024 | Harmony |
| E.R. Squibb & Sons, L.L.C. | $92.93 | 2019-2025 | Camzyos |
| Esperion Therapeutics, INC. | $74.94 | 2021-2022 | |
| Medtronic USA, INC. | $61.28 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $60.62 | 2019 | |
| Astellas Pharma US INC | $47.56 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $32.76 | 2023 | Opsumit |
| Tactile Systems Technology INC | $29.49 | 2023 | Flexitouch Plus, Entre Plus |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $23.50 | 2019 | |
| Genzyme Corporation | $18.16 | 2024 | |
| Gilead Sciences, INC. | $16.96 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.13 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.53 | 2022 | |
| Merck Sharp & Dohme LLC | $15.29 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $11.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Tanenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.